

# Dr Lalchandani Labs Ltd.

lalchandaniopathlab.com

November 14, 2025

## BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrp Code:** 541299

Dear Sir/Madam,

### **Sub: Outcome of Board Meeting Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. November 14, 2025, considered and approved, *inter alia*, the following business items:

1. Un-audited financial results of the Company for the half year ended September 30, 2025 along with Limited Review report by auditors thereon.

Meeting commenced at 05:00 P.M. and concluded at 06:00 P.M.

This is for your information and records.

Thanking You,

**FOR Dr Lalchandani Labs Limited**



**Arjan Lalchandani**  
Managing Director  
DIN: 07014579



**DrLalchandani**  
LABS

8010689689  
+91 76699 89614  
Say Hi

info@lalchandaniopathlab.com  
19C, Club Rd., Punjabi Bagh  
(w), New Delhi -110026  
M-20, GK-1, New Delhi-110048



Un-Audited Standalone Financial Results For The Half Year Ended And The Year Ended 30th September 2025

(INR Lacs.)

Sr. No.	Particulars	Half Year Ended			Yearly Ended	
		September 30, 2025 Un-audited	March 31, 2025 Audited	September 30, 2024 Un-audited	March 31, 2025 Audited	March 31, 2024 Audited
I	Revenue from Operations	205.10	232.84	212.54	445.38	480.94
II	Other Income	29.30	0.37	0.38	0.74	23.56
III	<b>Total Revenue (I+II)</b>	<b>234.40</b>	<b>233.21</b>	<b>212.92</b>	<b>446.13</b>	<b>504.50</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	67.60	59.73	35.89	95.61	205.49
	(b) Employee benefits expense	38.98	40.52	42.22	82.74	106.45
	(c) Finance Cost	0.81	3.26	5.28	8.54	38.35
	(d) Depreciation and amortisation expense	28.16	28.24	28.21	56.45	62.43
	(e) Other Expenses	72.80	93.68	81.01	174.69	149.05
	<b>Total Expenses</b>	<b>208.35</b>	<b>225.43</b>	<b>192.62</b>	<b>418.04</b>	<b>561.77</b>
V	<b>Profit before exceptional and extraordinary items and tax (III - IV)</b>	<b>26.06</b>	<b>7.78</b>	<b>20.30</b>	<b>28.08</b>	<b>(57.26)</b>
VI	Exceptional Items (refer note 5)	-	12.13	-	12.13	119.01
VII	<b>Profit/ (Loss) Before Tax (V - VI)</b>	<b>26.06</b>	<b>19.92</b>	<b>20.30</b>	<b>40.22</b>	<b>61.75</b>
VIII	<b>Tax Expenses :</b>					
	(1) Current Tax	6.56	(3.61)	5.11	1.50	-
	(2) Deferred Tax	-	(3.00)	-	(3.00)	-
IX	<b>Profit / (Loss) from Period from continuing Operations (VII - VIII)</b>	<b>19.50</b>	<b>26.53</b>	<b>15.19</b>	<b>41.72</b>	<b>61.75</b>
X	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XI	Tax Expense of Discontinuing Operations	-	-	-	-	-
XII	<b>Profit / (Loss) from Discontinuing Operations (After Tax X- XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit / (Loss) for the period (IX +XII)</b>	<b>19.50</b>	<b>26.53</b>	<b>15.19</b>	<b>41.72</b>	<b>61.75</b>
XIV	<b>Earnings Per Share of INR 10.00 Each (Not Annualised)</b>					
	(a) Basic (Rs.)	0.45	0.61	0.35	0.96	1.43
	(b) Diluted (Rs.)	0.45	0.61	0.35	0.96	1.43

Notes:

- The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14-11-2025.
- There were no investor complaints received / pending as at 30 September 2025.
- The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment-wise reporting is not applicable.
- The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.

For Dr Lalchandani Labs Limited,



(Dr. Arjan Lalchandani)  
Managing Director (DIN: 07014579 )  
New Delhi



**UN-AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 30.09.2025**

*Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	
		30.09.2025	31.03.2025
<b>1</b>	<b>Shareholders' Funds</b>		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	581.77	562.40
	(c) Money received against share warrants	-	-
	<b>Sub-total-Shareholders' Funds</b>	<b>1,015.08</b>	<b>995.71</b>
<b>2</b>	<b>Share application money pending allotment</b>		
<b>3</b>	<b>Non Current Liabilities</b>		
	(a) Long Term Borrowings	-	-
	(b) Deferred Tax Liability	11.20	12.89
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	<b>Sub-total-Non Current Liabilities</b>	<b>11.20</b>	<b>12.89</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	458.33	406.71
	(b) Trade Payables	-	-
	(i) Total Outstanding dues of micro enterprises and small enterprises	37.16	70.04
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	9.63	25.61
	(c) Other Current Liabilities	66.79	62.44
	(d) Short Term Provisions	10.90	1.50
	<b>Sub-total-Current Liabilities</b>	<b>582.81</b>	<b>566.28</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,609.08</b>	<b>1,574.88</b>
<b>II</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Fixed Assets		
	(i) Tangible assets	315.57	326.00
	(ii) Intangible assets	22.43	24.75
	(b) Non Current Investments	26.93	26.50
	(c) Long Term Loans & Advances	123.26	110.54
	(d) Other Non Current Assets	-	-
	<b>Sub-total-Non Current Assets</b>	<b>488.19</b>	<b>487.79</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	-	-
	(b) Inventories	118.08	129.43
	(c) Trade Receivables	563.28	525.86
	(d) Cash & cash equivalents	351.19	329.73
	(e) Short Term Loans & Advances	50.33	62.40
	(f) Other Current Assets	38.01	39.67
	<b>Sub-total-Current Assets</b>	<b>1,120.88</b>	<b>1,087.09</b>
	<b>TOTAL ASSETS</b>	<b>1,609.08</b>	<b>1,574.88</b>

**For Dr Lalchandani Labs Limited**

  
**Dr. Arjan Lalchandani**  
**(Managing Director)**  
**DIN: 07014579**  
**Place: New Delhi**



## Cash Flow Statement for the Year Ended 30.09.2025

<u>Particulars</u>	<u>30.09.2025</u> Amount	<u>31.03.2025</u> Amount
<b>A</b>		
<b><u>Cash Flow From Operating Activities</u></b>		
Net Profit/(Loss) Before Tax	26.06	40.22
Adjustment For:		
Depreciation & Amortisation	28.16	56.45
Interest Expense	0.81	8.54
Asset Written Off	0.02	0.01
Loss On Sale of Tangible Assets	-	0.11
Profit On Sale of Tangible Assets	-	(0.27)
Interest Income	(0.28)	(0.47)
Income Tax	(6.56)	(1.50)
<b><u>Operating Profit Before Working Capital Changes</u></b>	<b>48.21</b>	<b>103.08</b>
 <u>Changes in Working Capital</u>		
Change in Sundry Debtors	(37.42)	(55.45)
Change in Other Current Assets & Non Current Assets	1.66	4.47
Change in Trade Payables	(50.68)	(27.09)
Changes in Inventories	11.35	14.08
Change in Other Current Liabilities	4.35	3.72
Short Term Provisions	9.40	1.50
	<b>(61.33)</b>	<b>(58.78)</b>
 <b><u>Net Cash Flows From Operating Activities(A)</u></b>	<b>(13.12)</b>	<b>44.30</b>
 <b>B</b>		
<b><u>Cash Flow From Investing Activities</u></b>		
Purchase of Fixed Assets	(15.43)	(15.47)
Proceeds From Sale of Fixed Assets	-	7.50
Investment In Bank Deposits	(0.44)	14.23
Receipts from Loans & Advances	(12.72)	0.72
Interest Income	0.28	0.47
Loans and Advances given	12.07	(1.58)
 <b><u>Net Cash Flow From Investing Activities (B)</u></b>	<b>(16.24)</b>	<b>5.87</b>
 <b>C</b>		
<b><u>Cash Flow From Financing Activities</u></b>		
Long Term Borrowings taken	-	(26.29)
Short Term Borrowings	51.63	85.15
Interest Paid	(0.81)	(8.54)
 <b><u>Net Cash Flow From Financing Activities (C)</u></b>	<b>50.82</b>	<b>50.32</b>
 <u>Net Change in Cash (A+B+C)</u>	21.46	100.49
<b><u>Cash and Cash Equivalents at the Beginning of Year</u></b>	<b>329.73</b>	<b>229.24</b>
<b><u>Cash and Cash Equivalents at the End of Year</u></b>	<b>351.19</b>	<b>329.73</b>





## **LIMITED REVIEW REPORT**

**TO**

**THE BOARD OF DIRECTORS OF  
DR LALCHANDANI LABS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Dr Lalchandani Labs Limited** (“the Company”) for the half year ended 30<sup>th</sup> September 2025 (“the statement”). This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with Rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Our review is qualified for**

- **Company has not been able to pay installments for few months of term loans/unsecured loans during the period under review. Due to which they have not received the balance confirmation of various lenders. Company has valued the loan at the outstanding amount till the time they have paid the installment of term loans/unsecured loans. So the interest/penal interest levied by the varous lenders during the last months of previous financial year and the current period have not been captured in the financial statements. Hence the loss suffered by the company is understated by the aforesaid interest/penal interest.**
- **Gratuity Liability & Leave Encashment Liability is not provided for in the books of accounts of the company and is thus not in accordance with Accounting Standard 15 on “Employee Benefits” issued by the Institute of Chartered Accountants of India.**

**Emphasis of Matter**

- **The company has generally been irregular in deposits of statutory dues viz ESI, EPF and TDS for the financial year under consideration.**



Our conclusion is not modified in respect of above stated matters.

### Qualified Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For and on behalf of**  
**ATN & CO**  
**Chartered Accountants**  
**FRN – 024359N**



**CA Nitin Wadhwa**  
(Partner)  
Membership No. 511735  
UDIN: **25511735BMIZQP2479**

Place: New Delhi  
Date: 14<sup>th</sup> November 2025.